Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?
These terms may help you prepare for conversations with your care team about what’s next in your treatment journey. Click the words below to get definitions for frequently used phrases.
When tumors disappear with treatment.
Treatment that interferes with the effects of testosterone.
Possible side effect of PLUVICTO, someone with low blood platelet count struggles to stop bleeding. This could mean you bruise easily or bleed more than usual from a small cut.
Possible side effect of PLUVICTO, a low blood cell count affects your ability to fight infections. Symptoms may include tiredness, shortness of breath, and chest pain.
A type of advanced prostate cancer that has spread outside the prostate. It also no longer responds as well to certain hormone treatments.
The total percentage of patients whose cancer responds to treatment in a clinical trial. Their tumors disappear or shrink in size.
Measure of how long patients live after they are assigned treatment in a clinical trial.
When a treatment decreases a tumor’s size.
A substance made by the prostate that may be found in higher-than-normal levels in the blood of men who have prostate cancer. PSA levels are found through a blood test.
A biomarker commonly found on the outside of prostate cancer cells and some normal cells. A PSMA-PET scan can find PSMA+ cells in your body.
An imaging test that can help find PSMA+ cells, including prostate cancer cells, in your body.
In a clinical trial, how long patients live without their cancer getting worse after being assigned treatment. It is determined by imaging tests.
What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...
Approved Use
What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...
